Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ursodeoxycholic acid improves liver tests in chronic hepatitis - Results of a randomised controlled trial
Autore:
Bertolotti, M; Morselli-Labate, AM; Rusticali, AG; Loria, P; Carulli, N;
Indirizzi:
Univ Modena, Sch Med, Dept Internal Med, I-41100 Modena, Italy Univ Modena Modena Italy I-41100 ept Internal Med, I-41100 Modena, Italy Univ Bologna, Sch Med, Dept Internal Med & Gastroenterol, Bologna, Italy Univ Bologna Bologna Italy Internal Med & Gastroenterol, Bologna, Italy Sanofi Winthrop, Dept Med, Milan, Italy Sanofi Winthrop Milan ItalySanofi Winthrop, Dept Med, Milan, Italy
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 6, volume: 17, anno: 1999,
pagine: 425 - 434
SICI:
1173-2563(199906)17:6<425:UAILTI>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRIMARY BILIARY-CIRRHOSIS; CHRONIC ACTIVE HEPATITIS; PRIMARY SCLEROSING CHOLANGITIS; PLACEBO-CONTROLLED TRIAL; HYDROPHOBIC BILE-SALTS; DOUBLE-BLIND; CLINICAL-TRIAL; FOLLOW-UP; DISEASE; MULTICENTER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Bertolotti, M Policlin Modena, Div Med 3, Dipartimento Med Interna, Via Pozzo 71, I-41100 Policlin Modena Via Pozzo 71 Modena Italy I-41100 , I-41100
Citazione:
M. Bertolotti et al., "Ursodeoxycholic acid improves liver tests in chronic hepatitis - Results of a randomised controlled trial", CLIN DRUG I, 17(6), 1999, pp. 425-434

Abstract

Objective: The present study was designed to investigate the effect of ursodeoxycholic acid (UDCA), a drug widely utilised in the management of cholestatic conditions, on liver function tests and symptom relief in a group ofpatients with chronic hepatitis of different aetiologies. Patients and Design: 219 patients (128 males, 91 females) with a histological diagnosis of chronic hepatitis were enrolled in a multicentre randomised trial with UDCA (300mg twice daily orally) and folic acid as a placebo. Treatment was carried out for 6 months. Biochemical markers of liver diseaseactivity and scores for dyspeptic and systemic symptoms were determined. 213 patients completed the study (112 in the UDCA group, 101 in the placebo group). Results: UDCA induced a significant decrease (p < 0.001) in serum ALT, ASTand gamma-GT; folic acid induced a significant reduction (p < 0.05) of ALTat 4 and 6 months of treatment, and of AST at 6 months. As assessed by ANCOVA, the changes in enzyme levels were significantly (p < 0.001) more pronounced in the UDCA group compared with placebo. This was accompanied by a significantly higher (p < 0.05) percentage of patients showing normalisation of liver enzymes. Analysis of the interference of pre-existing factors on the biochemical outcome showed a more marked effect of UDCA in reducing ALT in patients with elevated gamma-GT. Finally, the frequency and score of most symptoms were significantly reduced (p < 0.05) with ursodeoxycholic acid. Conclusions: The effectiveness and tolerability of ursodeoxycholic acid make it worth consideration as a useful therapeutic tool in the treatment of chronic hepatitis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 03:13:52